VEGFR3/FLT4

Vascular endothelial growth factor receptor 3, VEGFR-3, Fms-like tyrosine kinase 4, FLT -4, Tyrosine-protein kinase receptor FLT4

Human

CMV017 pdf (datasheet)

100 μg

$690.00 BUY

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (recombinant human VEGFR -3/FLT-4) extracellular domain.

The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.

Vascular endothelial growth factor receptor 3

P35916

CMV017

Human VEGFR3

Mouse

Recombinant human soluble VEGFR-3 protein extracellular domain

IgG1

9D9

Lyophilized from PBS, pH 7.4 without preservative

Protein G Chromatography

Centrifuge vial prior to opening. Add sterile water to the vial to fully solubilize the antibody to a concentration of 0.1-1.0 mg/ml.

Western Blot: suggested concentration 1-5 µg/ml
ELISA: suggested concentration 1-5 µg/ml
IF/IHC: suggested concentration 1-10 µg/ml
FACS: suggested concentration 1-5 µg/ml

The optimal concentration should be determined by the user for each specific application.

The lyophilized antibody is stable for at least 1 year at -20°C to -80°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C to -80°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. Avoid repeated freeze-thaw cycles.